Myeloid effector cells in cancer

Area of Science:

• Immunology
• Cancer Biology
• Tumor Microenvironment

Background:

• Myeloid cells, such as macrophages and neutrophils, have been traditionally viewed as immunosuppressive in cancer immunity.
• While dendritic cells aid T cell-mediated tumor control, targeting other myeloid cells for immunosuppression has yielded limited clinical success.
• Existing immunotherapies primarily focus on reinvigorating tumor-reactive T cells.

Purpose of the Study:

• To re-evaluate the role of myeloid effector cells in tumor rejection.
• To challenge the notion that T cell cytotoxicity is the sole driver of immunotherapy-induced tumor regression.
• To highlight the necessity of myeloid effector cells in the context of successful cancer immunotherapy.

Main Methods:

• Review of recent studies on immune cell roles in immunotherapy.
• Analysis of T cell-mediated recruitment, activation, and reprogramming of myeloid cells.
• Interrogation of myeloid cell presence and function in therapy-driven tumor rejection.

Main Results:

• Therapy-activated T cells are key in recruiting and reprogramming myeloid effector cells within tumors.
• The presence and function of these reprogrammed myeloid cells are essential for tumor rejection.
• Recent immunotherapy successes underscore the importance of myeloid cells beyond T cell cytotoxicity.

Conclusions:

• Myeloid effector cells play a critical, multifaceted role in tumor rejection.
• Rethinking the function of myeloid cells in cancer immunity is vital for developing future immunotherapies.
• Targeting myeloid cell reprogramming by T cells may offer novel therapeutic strategies.